Results 121 to 130 of about 218,171 (299)

Deciphering the catalytic and pharmacological mechanisms of Coptis chinensis herbzymes to renovate intestinal microenvironment for colitis alleviation

open access: yesBMEMat, EarlyView.
The synthesized CCzymes possess both antioxidant enzyme activity and pharmacological properties inherent to Coptis chinensis. By their antioxidant enzyme activity, CCzymes can attenuate oxidative stress within the inflammatory region of ulcerative colitis (UC), while their pharmacological activity acts on macrophage polarization and the intestinal ...
Zhichao Deng   +10 more
wiley   +1 more source

Eudragit®‐engineered pH‐responsive probiotic microspheres with enhanced gastrointestinal resistance and prolonged storage stability for inflammatory bowel disease therapy

open access: yesBMEMat, EarlyView.
This study reports the development of AMS@Eud core‐shell microspheres, combining calcium alginate and pH‐responsive Eudragit® L100, which exhibit exceptional gastrointestinal resistance and long‐term storage stability (only 5.28%–9.09% viability loss over 35 days at 4–25°C), and effectively alleviate inflammatory bowel disease via gut microbiota ...
Ming Teng   +5 more
wiley   +1 more source

The Stressor Factors and Perceived Social Support in the Patients with Ulcerative Colitis

open access: yesمجله دانشکده پزشکی اصفهان, 2011
• Background: Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) characterized with chronic inflammation of mucosal surface of bowels. Genetic, immunologic, environmental and individual factors contribute disease have been identified in ...
Hamid Afshar   +4 more
doaj  

The ageing holobiont: crosstalk between telomere dynamics, oxidative stress and the gut microbiome

open access: yesBiological Reviews, EarlyView.
ABSTRACT The gut tissue is at the frontline of early onset of ageing. It exhibits high cell turnover rates and rapid telomere shortening, which can have systemic effects on the developing or senescing organism. We conducted a literature review of studies on the crosstalk between telomere length dynamics, telomerase activity, oxidative stress, and gut ...
Michael L. Pepke   +2 more
wiley   +1 more source

HLA TYPING OF ULCERATIVE COLITIS IN IRAN

open access: yesActa Medica Iranica, 1996
Ulcerative colitis is an acute or chronic inflammatory bowel disease that diffusely involves the colonic mucosa. the etiology of ulcerative colitis is unknown.
Froutan   +4 more
doaj  

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

open access: yesClinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska   +2 more
wiley   +1 more source

Isoform Specificity of a Compound Targeting Actin Filaments Containing Tropomyosin Tpm1.8/1.9

open access: yesCytoskeleton, EarlyView.
ABSTRACT The unbranched actin filaments in mammalian cells are usually composed of co‐polymers of a specific tropomyosin isoform with actin. Genetic manipulation has revealed that the tropomyosins largely define the functional properties of actin filaments in an isoform‐specific, non‐redundant manner.
Jeff Hook   +2 more
wiley   +1 more source

Market Access Analysis of Biologics and Small-Molecule Inhibitors for Inflammatory Bowel Disease Among US Health Insurance Policies. [PDF]

open access: yes, 2019
BACKGROUND AND AIMS:Treatment pathways for ulcerative colitis (UC) and Crohn's disease (CD) are shifting to a more individualized, risk-stratified approach.
Cao, Charlie   +5 more
core  

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Anita Iacono   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy